Expectations trend
FY2027 · fiscal year ending 2027-12-31 · fmp
Idexx Laboratories (IDXX)
NASDAQHealth CareMedical - Diagnostics & ResearchSnapshot 2026-11-05
$670.71-3.99%
Close 2026-11-05 · 1-day change
NASDAQHealth CareMedical - Diagnostics & ResearchSnapshot 2026-11-05
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
16.77 → 16.82 EPS · FY ending Dec 31, 2027 · 10 analysts
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
Change in the same fiscal period’s mean EPS estimate from Oct 6, 2026 to Nov 5, 2026: (new ÷ prior − 1). Contributor count changed from 10 to 10; this is not the number of analysts revising. The ±10% axis is a display range.
The EPS and P/E reference is not available for IDXX yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
4 published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
CAG Diagnostics recurring revenue growth | Idexx grows revenue about 10% a year, led by 14% growth in CAG Diagnostics recurring revenue. | Intact | YoY growth falls below 7% in FY26 | Revenue growth: 9.86% FY2026-Q3; GAAP. Published target: >=14% YoY. Annual target cannot be compared with a quarterly or TTM observation. Nov 2, 20269.861939 percent · calculatedLast status assessment Nov 5, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context |
Compare these dated observations with the operating requirements above
FY2027 · fiscal year ending 2027-12-31 · fmp
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Next earnings date unavailable
Observed price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
This is a durable-growth business thesis, supported by recurring diagnostic revenue and strong recent financial performance. The long-term thesis is intact, though its signal has softened from favorable to mildly favorable and management evidence is neutral overall.
IDEXX trades at a substantial premium to peers, reflecting expectations of durable growth. The valuation is tagged as justified, with only a small expectations gap, but confidence in that assessment is low.
For the near term, management is on track with its priorities: it has raised and narrowed 2026 revenue and EPS guidance, while recurring CAG Diagnostics revenue growth has stayed around 10%. Recent results have been strong, but the risk is not absent: past earnings surprises are trending down, and the evidence notes a prior deep miss.
The multi-year view depends on continued recurring diagnostics growth and management delivering on its raised guidance. A guidance cut after recent increases would damage credibility; weaker jobs data could also pressure the sector, while continued strength from healthcare bellwethers could support sector momentum.
Over the next 1 to 3 years, the business setup remains supported by consistent diagnostics growth and recent execution, but the premium valuation makes delivery important. The main swing factors are guidance credibility, recurring growth, and the broader healthcare backdrop. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Stated in 8 of 8 supplied quarters. Management reported: “Third Quarter Performance Highlights Companion Animal Group (“CAG”) CAG revenue growth was led by CAG Diagnostics recurring revenue growth of 11% as reported and organic, including 13% reported and 14% organic gains in International regions and 10% reported and organic growth in the U.S., outpacing sector growth levels.” “Strong same-store volume growth, IDEXX innovation benefits, net customer gains and premium instrument installed base expansion drove double-digit CAG Diagnostics recurring revenue growth.” Revenue was $1.214 billion in 2026-Q3.
Earnings per share outlook | The company raised its 2026 revenue guidance to about $4.7 billion and EPS outlook to $14.45. | Intact | EPS falls below $13.00 in FY26 | Diluted EPS: $4.01 per share FY2026-Q3; GAAP. Published target: >=$14.45 per share. Annual target cannot be compared with a quarterly or TTM observation. Nov 2, 20264.01 USD/share · source valueLast status assessment Nov 5, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Operating profit margin | A supporting condition in Idexx Laboratories's published investment case. The stated target is ~31.7%. | Intact | operating margin falls below 30% in FY26 | Operating margin: 33.14% FY2026-Q3; GAAP. Published target: ~31.7%. Annual target cannot be compared with a quarterly or TTM observation. Nov 2, 202633.135871 percent · calculatedLast status assessment Nov 5, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Total company revenue growth | A primary condition in Idexx Laboratories's published investment case. The stated target is >=9% YoY. | Intact | revenue growth falls below 7% in FY26 | Revenue growth: 9.86% FY2026-Q3; GAAP. Published target: >=9% YoY. Annual target cannot be compared with a quarterly or TTM observation. Nov 2, 20269.861939 percent · calculatedLast status assessment Nov 5, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$16.56 → $16.82 · observed estimates
$5.12B → $5.16B · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-07-24 | $16.56 | $5,120,802,724 | 10 / 11 |
| 2026-07-25 | $16.56 | $5,120,802,724 | 10 / 11 |
| 2026-07-26 | $16.56 | $5,120,802,724 | 10 / 11 |
| 2026-07-27 | $16.56 | $5,120,802,724 | 10 / 11 |
| 2026-07-28 | $16.56 | $5,120,802,724 | 10 / 11 |
| 2026-07-29 | $16.52 | $5,114,742,840 | 14 / 14 |
| 2026-07-30 | $16.56 | $5,121,185,876 | 10 / 11 |
| 2026-07-31 | $16.56 | $5,121,185,876 | 10 / 11 |
| 2026-08-01 | $16.56 | $5,121,185,876 | 10 / 11 |
| 2026-08-02 | $16.52 | $5,114,742,840 | 14 / 14 |
| 2026-08-03 | $16.52 | $5,114,742,840 | 14 / 14 |
| 2026-08-04 | $16.52 | $5,114,742,840 | 14 / 14 |
| 2026-08-05 | $16.52 | $5,114,742,840 | 14 / 14 |
| 2026-08-06 | $16.52 | $5,114,742,840 | 14 / 14 |
| 2026-08-07 | $16.74 | $5,133,839,495 | 10 / 11 |
| 2026-08-08 | $16.74 | $5,133,839,495 | 10 / 11 |
| 2026-08-09 | $16.69 | $5,140,055,800 | 13 / 13 |
| 2026-08-10 | $16.74 | $5,133,839,495 | 10 / 11 |
| 2026-08-12 | $16.74 | $5,133,839,495 | 10 / 11 |
| 2026-08-13 | $16.74 | $5,133,839,495 | 10 / 11 |
| 2026-08-14 | $16.74 | $5,133,839,495 | 10 / 11 |
| 2026-08-15 | $16.74 | $5,133,839,495 | 10 / 11 |
| 2026-08-16 | $16.74 | $5,133,839,495 | 10 / 10 |
| 2026-08-17 | $16.74 | $5,133,839,495 | 10 / 10 |
| 2026-08-18 | $16.74 | $5,133,839,495 | 10 / 10 |
| 2026-08-19 | $16.74 | $5,133,839,495 | 10 / 10 |
| 2026-08-20 | $16.77 | $5,141,780,024 | 10 / 10 |
| 2026-08-21 | $16.77 | $5,141,780,024 | 10 / 10 |
| 2026-08-22 | $16.77 | $5,141,780,024 | 10 / 10 |
| 2026-08-23 | $16.77 | $5,141,780,024 | 10 / 10 |
| 2026-08-24 | $16.77 | $5,141,780,024 | 10 / 10 |
| 2026-08-25 | $16.77 | $5,141,780,024 | 10 / 10 |
| 2026-08-26 | $16.77 | $5,141,780,024 | 10 / 10 |
| 2026-08-27 | $16.77 | $5,141,780,024 | 10 / 10 |
| 2026-08-28 | $16.77 | $5,141,780,024 | 10 / 10 |
| 2026-08-29 | $16.77 | $5,141,780,024 | 10 / 10 |
| 2026-08-30 | $16.77 | $5,141,780,024 | 10 / 10 |
| 2026-08-31 | $16.77 | $5,141,780,024 | 10 / 10 |
| 2026-09-01 | $16.77 | $5,141,780,024 | 10 / 10 |
| 2026-09-02 | $16.77 | $5,141,780,024 | 10 / 10 |
| 2026-09-03 | $16.77 | $5,141,780,024 | 10 / 10 |
| 2026-09-04 | $16.77 | $5,141,780,024 | 10 / 10 |
| 2026-09-05 | $16.77 | $5,141,780,024 | 10 / 10 |
| 2026-09-06 | $16.77 | $5,141,780,024 | 10 / 10 |
| 2026-09-07 | $16.77 | $5,141,780,024 | 10 / 10 |
| 2026-09-08 | $16.77 | $5,141,780,024 | 10 / 10 |
| 2026-09-09 | $16.77 | $5,141,780,024 | 10 / 10 |
| 2026-09-10 | $16.77 | $5,141,780,024 | 10 / 10 |
| 2026-09-11 | $16.77 | $5,141,780,024 | 10 / 10 |
| 2026-09-12 | $16.77 | $5,141,780,024 | 10 / 10 |
| 2026-09-13 | $16.77 | $5,141,780,024 | 10 / 10 |
| 2026-09-14 | $16.77 | $5,141,780,024 | 10 / 10 |
| 2026-09-15 | $16.77 | $5,141,780,024 | 10 / 10 |
| 2026-09-16 | $16.77 | $5,141,780,024 | 10 / 10 |
| 2026-09-17 | $16.77 | $5,142,233,335 | 10 / 10 |
| 2026-09-18 | $16.77 | $5,142,233,335 | 10 / 10 |
| 2026-09-19 | $16.77 | $5,142,233,335 | 10 / 10 |
| 2026-09-20 | $16.77 | $5,142,233,335 | 10 / 10 |
| 2026-09-21 | $16.77 | $5,142,233,335 | 10 / 10 |
| 2026-09-22 | $16.77 | $5,142,233,335 | 10 / 10 |
| 2026-09-23 | $16.77 | $5,142,233,335 | 10 / 10 |
| 2026-09-24 | $16.77 | $5,142,233,335 | 10 / 10 |
| 2026-09-25 | $16.77 | $5,142,233,335 | 10 / 10 |
| 2026-09-26 | $16.77 | $5,142,233,335 | 10 / 10 |
| 2026-09-27 | $16.77 | $5,142,233,335 | 10 / 10 |
| 2026-09-28 | $16.77 | $5,142,233,335 | 10 / 10 |
| 2026-09-29 | $16.77 | $5,142,581,630 | 10 / 10 |
| 2026-09-30 | $16.77 | $5,142,581,630 | 10 / 10 |
| 2026-10-01 | $16.77 | $5,142,581,630 | 10 / 10 |
| 2026-10-02 | $16.77 | $5,142,581,630 | 10 / 10 |
| 2026-10-03 | $16.77 | $5,142,579,558 | 10 / 10 |
| 2026-10-04 | $16.77 | $5,142,579,558 | 10 / 10 |
| 2026-10-05 | $16.77 | $5,142,579,558 | 10 / 10 |
| 2026-10-06 | $16.77 | $5,142,579,558 | 10 / 10 |
| 2026-10-07 | $16.77 | $5,142,579,558 | 10 / 10 |
| 2026-10-08 | $16.77 | $5,142,579,558 | 10 / 10 |
| 2026-10-09 | $16.77 | $5,142,579,558 | 10 / 10 |
| 2026-10-10 | $16.77 | $5,142,579,558 | 10 / 10 |
| 2026-10-11 | $16.77 | $5,142,579,558 | 10 / 10 |
| 2026-10-12 | $16.77 | $5,142,579,558 | 10 / 10 |
| 2026-10-13 | $16.75 | $5,140,581,261 | 10 / 10 |
| 2026-10-14 | $16.75 | $5,140,581,261 | 10 / 10 |
| 2026-10-15 | $16.75 | $5,140,581,261 | 10 / 10 |
| 2026-10-16 | $16.75 | $5,140,581,261 | 11 / 11 |
| 2026-10-17 | $16.75 | $5,140,581,261 | 11 / 11 |
| 2026-10-18 | $16.81 | $5,152,989,422 | 10 / 11 |
| 2026-10-19 | $16.81 | $5,152,989,422 | 10 / 11 |
| 2026-10-20 | $16.81 | $5,152,989,422 | 10 / 11 |
| 2026-10-21 | $16.81 | $5,152,989,422 | 10 / 11 |
| 2026-10-22 | $16.78 | $5,147,072,755 | 10 / 11 |
| 2026-10-23 | $16.78 | $5,147,072,755 | 10 / 11 |
| 2026-10-24 | $16.78 | $5,147,072,755 | 10 / 11 |
| 2026-10-25 | $16.78 | $5,147,072,755 | 10 / 11 |
| 2026-10-26 | $16.78 | $5,147,072,755 | 10 / 11 |
| 2026-10-27 | $16.78 | $5,147,072,755 | 10 / 11 |
| 2026-10-28 | $16.77 | $5,144,660,534 | 10 / 11 |
| 2026-10-29 | $16.77 | $5,144,660,534 | 10 / 11 |
| 2026-10-30 | $16.77 | $5,144,660,534 | 10 / 11 |
| 2026-10-31 | $16.76 | $5,143,227,200 | 10 / 11 |
| 2026-11-01 | $16.74 | $5,134,517,416 | 10 / 11 |
| 2026-11-02 | $16.74 | $5,134,517,416 | 10 / 11 |
| 2026-11-03 | $16.79 | $5,153,187,587 | 9 / 11 |
| 2026-11-04 | $16.82 | $5,158,616,852 | 10 / 11 |
| 2026-11-05 | $16.82 | $5,158,616,852 | 10 / 11 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Latest: 9 Buy / Strong Buy · 4 Hold · 2 Sell / Strong Sell
Recent actions · Oct 7–Nov 5 · 4 recorded
1 raises · 0 cuts · 0 unchanged · 1 without a comparable prior
Oct 7, 2026–Nov 5, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
4 of 4 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.